LERITINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Leritine, and when can generic versions of Leritine launch?
Leritine is a drug marketed by Merck and is included in two NDAs.
The generic ingredient in LERITINE is anileridine hydrochloride. Additional details are available on the anileridine hydrochloride profile page.
Summary for LERITINE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 13 |
Patent Applications: | 4,191 |
Formulation / Manufacturing: | see details |
DailyMed Link: | LERITINE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for LERITINE
US Patents and Regulatory Information for LERITINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck | LERITINE | anileridine phosphate | INJECTABLE;INJECTION | 010520-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Merck | LERITINE | anileridine hydrochloride | TABLET;ORAL | 010585-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |